Uncategorized-EN
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas (DOREMY) (2)
Agents: Radiotherapy Phase II Status Closed, active Sponsor The Netherlands Cancer Institute Further information: https://clinicaltrials.gov/ct2/show/NCT02106312 WHO is the trial for? Adult patients with confirmed Myxoid Liposarcoma (MLS) of the soft tissue without metastasis or with only a small number of metastasis (oligometastasis) Overall health status of the patient has to be good (ECOG…
Read MoreThree versus five years of adjuvant imatinib as treatment of patients with operable GIST (SSG XXII)
Three years of imatinib (Gleevec, Glivec) is considered the standard duration of adjuvant (preventive) therapy for patients with operable GIST, but a high risk of relapse. Yet, many patients are still at a high risk of GIST recurrence after completion of 3 years of adjuvant imatinib, and might benefit from further adjuvant imatinib therapy. The…
Read MoreUnesbulin in Advanced Leiomyosarcoma (SUNRISELMS)
Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) (SUNRISELMS) Agents: Unesbulin in combination with dacabazine Phase II/III Status Recruiting Sponsor PTC Therapeutics Further information: https://clinicaltrials.gov/ct2/show/NCT05269355 This study compares the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in patients with unresectable or metastatic, relapsed or refractory leiomyosarcoma (LMS) who have received at…
Read MoreNirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis
Trial name: Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis Agents: Nirogacestat vs. placebo Phase III Status Closed, active Sponsor SpringWorks Therapeutics, Inc. This randomized, double-blind, placebo-controlled, phase 3 trial evaluates nirogacestat versus placebo in the treatment of adult patients with progressing desmoid tumors/aggressive fibromatosis. Further information: https://www.clinicaltrials.gov/ct2/show/study/NCT03785964?term=Nirogacestat&draw=2&rank=1&show_locs=Y#locn WHO is the trial…
Read MoreSTRASS Trial
Surgery With or Without Radiation Therapy in Treating Patients With Previously Untreated Nonmetastatic Retroperitoneal Soft Tissue Sarcoma (STRASS) Agents: Radiation therapy followed by surgery vs. surgery alone Phase III Status Open, recruiting Sponsor European Organisation for Research and Treatment of Cancer – EORTC Further information Link zu Details (to be inserted) WHO is the trial…
Read MoreAbout us (2)
{loadposition position-15} Sarcoma Patients EuroNet Association (SPAEN), the international Network of Sarcoma, GIST and Desmoid Patient Advocacy Groups, was founded in April 2009 with the aim of extending information services, patient support and advocacy to patient organisations for the benefit of sarcoma patients across the whole of Europe and internationally. Acting in partnership with…
Read MoreSPAGN Annual Conferences
SPAEN/SPAGN Annual Conferences Since 2010, SPAEN/SPAGN has been dedicated to organizing annual conferences that unite sarcoma, GIST, and desmoid patient groups with experts, researchers, and industry leaders. These in-person events have consistently brought together 80-100 participants from over 25 countries, including patient advocates, leading sarcoma experts, and pharmaceutical representatives. Each three-day conference focuses on learning…
Read More2021 SPAEN Virtual Conference: 22 – 24 April 2021
11th SPAEN Annual Conference Virtual, global, informative and collaborative The ongoing pandemic and the decision to hold the SPAEN 2021 Annual Conference as a virtual meeting has allowed us to have even more participants in 2021! Over 200 registered participants attended the SPAEN Conference 2021 with internationally leading sarcoma experts and patient advocates representing organizations…
Read MoreAnnual Conferences
Previous SPAEN Conferences 8th SPAEN Annual Conference 2018 Milan/ItalyThe SPAEN Annual Conference 2018 was held – for the first time ever – in conjunction with a professional meeting. SPAEN and European Society of Medical Oncology (ESMO) have agreed to combine their meetings and hold the SPAEN conference just before the ESMO GIST & Sarcoma Symposium…
Read MoreSPAEN Advocacy in Action Award 2017: And the award goes to…
Patient advocacy ensures that people are heard, take action and ultimately improve situations, achieve changes or help to fulfil unmet medical needs. We decided that it is time to shout out about how important patient advocacy in sarcomas is – for patients, caregivers, healthcare professionals or anyone interested in sarcomas. We are very…
Read More